SCYNEXIS, Inc. Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs
SCYNEXIS, Inc. (SCYX) had Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs of $0 as of 2014-12-31, per its 8-K filed 2015-10-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts · last filed 2015-10-30
- 2014-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $0.00.
- 2013-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $800.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs |
|---|---|
| 2014-12-31 | $0.00 8-K · filed 2015-10-30 |
| 2013-12-31 | $800.00K 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |